DNTH-103
- Generic Name
- DNTH-103
Dianthus Therapeutics Completes Enrollment in Phase 2 MaGic Trial for Generalized Myasthenia Gravis Treatment
• Dianthus Therapeutics has successfully enrolled 65 patients in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis, exceeding the target of 60 patients with top-line results expected in September 2025.
• DNTH103 is a monoclonal antibody designed to selectively inhibit the classical complement pathway by targeting the C1s protein, potentially offering patients a convenient self-administered subcutaneous injection dosed once every two weeks.
• The company is building a neuromuscular franchise with DNTH103, which is also being evaluated in Phase 3 trials for Chronic Inflammatory Demyelinating Polyneuropathy and Phase 2 trials for Multifocal Motor Neuropathy, with results expected in the second half of 2026.
Complement Inhibitors Show Promise in Diverse Clinical Trials
• The complement inhibitors market is experiencing growth due to increased understanding of the complement system's role in rare and chronic diseases.
• Over 40 companies are actively developing more than 50 complement inhibitor therapies, targeting conditions like PNH, aHUS and Guillain-Barré syndrome.
• Clinical trials are underway for novel inhibitors like Gefurulimab, ANX005 and DNTH103, showing potential in myasthenia gravis and multifocal motor neuropathy.
• Recent FDA clearances and orphan drug designations highlight the increasing regulatory support for complement-targeted therapies, fostering innovation.
Hesperos' Human-on-a-Chip Technology Supports Phase II Trial of DNTH103 for Generalized Myasthenia Gravis
• Hesperos' Human-on-a-Chip technology supported Dianthus Therapeutics' Investigational New Drug submission for DNTH103, a monoclonal antibody, to the FDA.
• DNTH103 is currently in a Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG), a chronic autoimmune disorder.
• Preclinical data using Hesperos' neuromuscular junction model demonstrated DNTH103 improved nerve cell transmission and decreased muscle fatigue in gMG patient serum.
• The Human-on-a-Chip platform offers physiologically relevant functional readouts, potentially predicting therapeutic profiles and accelerating drug development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath